Search research articles
Contact Us
Filters
Showing results (121-130 of 148) with videos related to
Page
of 15
Sort By:
The Oncologist
|
December 3, 2025
NCI 10211: a phase II, single-arm study of berzosertib in combination with irinotecan in patients with advanced TP53 mutant gastroesophageal cancer
Margaret C Wheless, Shannon Stockton, Heloisa P Soares, et al.
The Oncologist
|
January 17, 2020
Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy
Satya Das, Kristen K Ciombor, Sigurdis Haraldsdottir, et al.
JAMA Network Open
|
January 19, 2022
External Validation of a Clinical Score for Patients With Neuroendocrine Tumors Under Consideration for Peptide Receptor Radionuclide Therapy
Satya Das, Aman Chauhan, Liping Du, et al.
Current Problems in Cancer
|
April 18, 2021
Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib
Shivaani Kummar, Jordan Berlin, Leo Mascarenhas, et al.
Cancer Chemotherapy and Pharmacology
|
October 15, 2013
Phase 1 study of N(1),N(11)‑diethylnorspermine (DENSPM) in patients with advanced hepatocellular carcinoma
Lipika Goyal, Jeffrey G Supko, Jordan Berlin, et al.
Nature Medicine
|
January 16, 2018
Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models
Michael L Schulte, Allie Fu, Ping Zhao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 28, 2021
Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513
E Gabriela Chiorean, Katherine A Guthrie, Philip A Philip, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 8, 2024
Management of Locally Advanced Rectal Cancer: ASCO Guideline
Aaron J Scott, Erin B Kennedy, Jordan Berlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 6, 2018
Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study
Dejan Juric, Jordi Rodon, Josep Tabernero, et al.
Journal of the American College of Radiology : JACR
|
November 5, 2025
ACR Appropriateness Criteria® Staging and Disease Monitoring of Colon Cancer and Appendiceal Cancer
, Elena K Korngold, Avinash R Kambadakone, et al.
Page
of 15
Search research articles
Search
Showing results (121-130 of 148) with videos related to
Sort By:
Page
of 15
The Oncologist
|
December 3, 2025
NCI 10211: a phase II, single-arm study of berzosertib in combination with irinotecan in patients with advanced TP53 mutant gastroesophageal cancer
Margaret C Wheless, Shannon Stockton, Heloisa P Soares, et al.
The Oncologist
|
January 17, 2020
Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy
Satya Das, Kristen K Ciombor, Sigurdis Haraldsdottir, et al.
JAMA Network Open
|
January 19, 2022
External Validation of a Clinical Score for Patients With Neuroendocrine Tumors Under Consideration for Peptide Receptor Radionuclide Therapy
Satya Das, Aman Chauhan, Liping Du, et al.
Current Problems in Cancer
|
April 18, 2021
Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib
Shivaani Kummar, Jordan Berlin, Leo Mascarenhas, et al.
Cancer Chemotherapy and Pharmacology
|
October 15, 2013
Phase 1 study of N(1),N(11)‑diethylnorspermine (DENSPM) in patients with advanced hepatocellular carcinoma
Lipika Goyal, Jeffrey G Supko, Jordan Berlin, et al.
Nature Medicine
|
January 16, 2018
Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models
Michael L Schulte, Allie Fu, Ping Zhao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 28, 2021
Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513
E Gabriela Chiorean, Katherine A Guthrie, Philip A Philip, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 8, 2024
Management of Locally Advanced Rectal Cancer: ASCO Guideline
Aaron J Scott, Erin B Kennedy, Jordan Berlin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 6, 2018
Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study
Dejan Juric, Jordi Rodon, Josep Tabernero, et al.
Journal of the American College of Radiology : JACR
|
November 5, 2025
ACR Appropriateness Criteria® Staging and Disease Monitoring of Colon Cancer and Appendiceal Cancer
, Elena K Korngold, Avinash R Kambadakone, et al.
Page
of 15